



## Translational Medicine and Therapeutics (TMAT) in Scotland

### Launch of the Scottish Clinical Pharmacology and Pathology Programme (SCP<sup>3</sup>) and the Scottish Translational Medicine and Therapeutics Initiative (STMTI)

The Wellcome Auditorium, Queen's Medical Research Institute, Edinburgh  
Monday 22<sup>nd</sup> November 2010, 10.00am to 4.00pm

10.00am	Welcome	Professor Sir John Savill Head of CMVM, The University of Edinburgh Chief Executive, MRC
10.15am	The Rise of TMAT and Regulatory Science. Two Sides of One Coin?	Professor Garret FitzGerald Associate Dean for Translational Research University of Pennsylvania
11.15am	TMAT in Scotland	Professor Jonathan Seckl Executive Dean of Medicine The University of Edinburgh
11.40am	Scottish Translational Medicine and Therapeutics Initiative (STMTI)	Professor David Webb Director, STMTI The University of Edinburgh
12.05pm	Scottish Clinical Pharmacology and Pathology Programme (SCP <sup>3</sup> )	Professor Iain McInnes Director, SCP <sup>3</sup> The University of Glasgow
12.30pm	Engaging with Industry in Translational Research	Dr Allison Jeynes-Ellis Medical and Innovation Director ABPI
1.00pm	The Pivotal Role of Translational Medicine in Pharma R&D	Dr Steve Felstead Vice-President of Research Pfizer
1.30pm	Lunch	
2.30pm	Clinical Research Training in the Next 10 Years: an MRC Perspective?	Dr Peter Dukes Strategy and Liaison Manager Medical Research Council



3.00pm	Training the Next Generation of Translational Researcher	Dr John Williams Head of Clinical Activities The Wellcome Trust
3.30pm	Can We Make a Difference? – Pulmonary Hypertension as a Paradigm	Professor Martin Wilkins Professor of Clinical Pharmacology Imperial College, London
4.00pm	Close	Professor Andrew Morris Professor of Diabetic Medicine The University of Dundee